BJP MLA slams Serum India over anti-COVID vaccine pricing, calls its CEO Adar Poonawalla ”dacoit”
PTI, Apr 22, 2021, 5:18 PM IST
Lucknow: Upset over anti-coronavirus vaccine pricing by the Serum Institute of India (SII), a BJP MLA has compared its CEO Adar Poonawalla with a “dacoit” and asked the government to “acquire” the company under the Epidemic Diseases Act.
Gorakhpur MLA Radha Mohan Das Agrawal made the remarks after SII on Wednesday announced a price of Rs 600 per dose for Covishield supplies to private hospitals and Rs 400 per dose to state governments.
“@adarpoonawalla you are worse than a dacoit. @PMOIndia @AmitShah @blsanthosh @drharshvardhan should acquire your factory under the epidemic act,” the MLA, who is also a doctor, said in a tweet in Hindi on Wednesday.
In a series of tweets, Agrawal also referred to the Swaminathan Commission’s formula for agriculture costs and prices.
The world’s largest vaccine maker announced the pricing of AstraZeneca shots it manufactures at its Pune facility, following the government decision to open up inoculation to all citizens above 18 years of age.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Teen stabs man to death at railway station in Mumbai after quarrel over local train seat
War has endangered future of 2.5 billion children of world: UP CM Adityanath
UP man gets 10-yr jail term for murder attempt on father
SC notice to Gujarat govt on Asaram’s plea seeking suspension of sentence in 2013 rape case
US charges against Adani, 7 others could lead to arrest warrants, extradition bid: attorney
MUST WATCH
Latest Additions
Teen stabs man to death at railway station in Mumbai after quarrel over local train seat
War has endangered future of 2.5 billion children of world: UP CM Adityanath
UP man gets 10-yr jail term for murder attempt on father
Cement mixer truck overturns near Ambagilu
SC notice to Gujarat govt on Asaram’s plea seeking suspension of sentence in 2013 rape case
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.